oxacillin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, 6-aminopenicillanic acid derivatives 2006 66-79-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • oxacillin sodium hydrate
  • oxacillin
  • oxazocilline
  • oxazocillin
  • oxacillin sodium
An antibiotic similar to FLUCLOXACILLIN used in resistant staphylococci infections.
  • Molecular weight: 401.44
  • Formula: C19H19N3O5S
  • CLOGP: 2.09
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 112.74
  • ALOGS: -3.67
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g O
2 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 46 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 249.10 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 33 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.19 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 6.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.07 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
April 8, 1971 FDA SANDOZ

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 91.14 42.29 27 632 33809 63454554

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 57.06 37.57 26 1164 32986 34922755
Acute kidney injury 46.24 37.57 54 1136 304934 34650807
Toxic skin eruption 40.32 37.57 15 1175 11370 34944371
Renal tubular necrosis 39.04 37.57 16 1174 15664 34940077

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 134.62 34.36 51 1682 64193 79678462
Eosinophilia 73.71 34.36 30 1703 45315 79697340
Acute kidney injury 71.90 34.36 71 1662 519333 79223322
Toxic skin eruption 40.51 34.36 16 1717 22277 79720378
Renal tubular necrosis 38.71 34.36 16 1717 25023 79717632
Device related infection 36.98 34.36 17 1716 34277 79708378

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01CF04 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
BETA-LACTAM ANTIBACTERIALS, PENICILLINS
Beta-lactamase resistant penicillins
FDA CS M0016152 Penicillins
FDA EPC N0000175497 Penicillin-class Antibacterial
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:33282 bactericides
CHEBI has role CHEBI:36047 antibacterial drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Staphylococcal meningitis indication 12166008
Infection of skin AND/OR subcutaneous tissue indication 19824006
Staphylococcal pneumonia indication 22754005
Sinusitis indication 36971009
Lower respiratory tract infection indication 50417007
Staphylococcal infectious disease indication 56038003
Staphylococcal endocarditis indication 73028002
Acute bacterial sinusitis indication 75498004
Infection of bone indication 111253001
Staphylococcal septicemia indication 111821004
Pharyngitis indication 405737000 DOID:2275
Infection due to Staphylococcus aureus indication 406602003
Osteomyelitis due to Staphylococcus aureus indication 428783003
Sepsis due to Staphylococcus aureus indication 448417001
Staphylococcus Epidermidis Urinary Tract Infection indication
Staphylococcus Aureus Joint Infection indication
Staphylococcus Aureus Urinary Tract Infection indication
Continuation Therapy for Chronic Osteomyelitis indication
Staphylococcal Prosthetic Heart Valve Endocarditis indication
Staphylococcus Aureus Bronchitis indication
Continuation Therapy for Acute Osteomyelitis indication
Pyrexia of unknown origin off-label use 7520000
Cholangitis off-label use 82403002 DOID:9446
Bacterial endocarditis off-label use 301183007
Diabetic Foot Infection Due to Gram-Positive Bacteria off-label use
Kidney disease contraindication 90708001 DOID:557
Infectious mononucleosis contraindication 271558008 DOID:8568
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.76 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Prostaglandin G/H synthase 2 Enzyme IC50 5.85 WOMBAT-PK
Prostaglandin G/H synthase 1 Enzyme IC50 7.02 WOMBAT-PK
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A Enzyme IC50 5.04 WOMBAT-PK
Penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL
Penicillin-binding protein 1A Enzyme WOMBAT-PK

External reference:

IDSource
4019867 VUID
N0000147953 NUI
D00929 KEGG_DRUG
7240-38-2 SECONDARY_CAS_RN
4018149 VANDF
4019867 VANDF
C0029983 UMLSCUI
CHEBI:7809 CHEBI
CHEMBL819 ChEMBL_ID
CHEMBL3989567 ChEMBL_ID
CHEMBL693 ChEMBL_ID
D010068 MESH_DESCRIPTOR_UI
DB00713 DRUGBANK_ID
6196 PUBCHEM_CID
10943 IUPHAR_LIGAND_ID
1372 INN_ID
UH95VD7V76 UNII
7773 RXNORM
4479 MMSL
5207 MMSL
d00115 MMSL
002690 NDDF
004834 NDDF
372868007 SNOMEDCT_US
83201006 SNOMEDCT_US
85724000 SNOMEDCT_US
0WO PDB_CHEM_ID
1S6 PDB_CHEM_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
OXACILLIN HUMAN PRESCRIPTION DRUG LABEL 1 0338-1013 INJECTION, SOLUTION 1 g INTRAVENOUS NDA 24 sections
OXACILLIN HUMAN PRESCRIPTION DRUG LABEL 1 0338-1013 INJECTION, SOLUTION 1 g INTRAVENOUS NDA 24 sections
OXACILLIN HUMAN PRESCRIPTION DRUG LABEL 1 0338-1015 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 24 sections
OXACILLIN HUMAN PRESCRIPTION DRUG LABEL 1 0338-1015 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 24 sections
Oxacillin HUMAN PRESCRIPTION DRUG LABEL 1 22607-698 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 21 sections
Oxacillin HUMAN PRESCRIPTION DRUG LABEL 1 22607-699 INJECTION, POWDER, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 21 sections
Oxacillin HUMAN PRESCRIPTION DRUG LABEL 1 25021-146 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 24 sections
Oxacillin HUMAN PRESCRIPTION DRUG LABEL 1 25021-162 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 24 sections
Oxacillin HUMAN PRESCRIPTION DRUG LABEL 1 25021-162 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 24 sections
Oxacillin HUMAN PRESCRIPTION DRUG LABEL 1 25021-163 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 24 sections
Oxacillin HUMAN PRESCRIPTION DRUG LABEL 1 25021-163 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 24 sections
Oxacillin Human Prescription Drug Label 1 55150-127 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 22 sections
Oxacillin Human Prescription Drug Label 1 55150-127 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 22 sections
Oxacillin Human Prescription Drug Label 1 55150-127 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 22 sections
Oxacillin Human Prescription Drug Label 1 55150-127 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 22 sections
Oxacillin Human Prescription Drug Label 1 55150-128 INJECTION, POWDER, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 22 sections
Oxacillin Human Prescription Drug Label 1 55150-128 INJECTION, POWDER, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 22 sections
Oxacillin Human Prescription Drug Label 1 55150-128 INJECTION, POWDER, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 22 sections
Oxacillin Human Prescription Drug Label 1 55150-128 INJECTION, POWDER, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 22 sections
Oxacillin Human Prescription Drug Label 1 55150-129 POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 22 sections
Oxacillin Human Prescription Drug Label 1 55150-129 POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 22 sections
Oxacillin Human Prescription Drug Label 1 55150-129 POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 22 sections
Oxacillin Human Prescription Drug Label 1 55150-129 POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 22 sections
Oxacillin HUMAN PRESCRIPTION DRUG LABEL 1 63323-811 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 23 sections
Oxacillin HUMAN PRESCRIPTION DRUG LABEL 1 63323-812 INJECTION, POWDER, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 12 sections
Oxacillin HUMAN PRESCRIPTION DRUG LABEL 1 63323-813 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 12 sections
Oxacillin HUMAN PRESCRIPTION DRUG LABEL 1 64679-698 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 20 sections
Oxacillin HUMAN PRESCRIPTION DRUG LABEL 1 64679-699 INJECTION, POWDER, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 20 sections
Oxacillin HUMAN PRESCRIPTION DRUG LABEL 1 64679-700 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 19 sections
Oxacillin HUMAN PRESCRIPTION DRUG LABEL 1 66794-225 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 11 sections